Completed PHASE3 INTERVENTIONAL 2-arm NCT01525836

rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

Recombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.

Sponsor: First Hospital of China Medical University

Conditions Idiopathic Thrombocytopenic Purpura Purpura

Interventions Rituximab rituximab; recombinant human thrombopoietin (rhTPO)

Updated 5 times since 2017 Last updated: Apr 18, 2016 Started: May 31, 2011 Primary completion: Dec 31, 2013 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Idiopathic Thrombocytopenic Purpura and Purpura and is currently completed. First Hospital of China Medical University leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Hospital of China Medical University
Shandong Provincial Hospital
Shandong University
Shenzhen Second People's Hospital
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
The First Affiliated Hospital of Anhui Medical University
The First Affiliated Hospital of Dalian Medical University

Data source: Shandong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China